Hologic Inc. (HOLX) Short Interest Update
Hologic Inc. (NASDAQ:HOLX) was the recipient of a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 6,461,519 shares, an increase of 61.3% from the September 15th total of 4,006,600 shares. Approximately 2.3% of the company’s shares are sold short. Based on an average daily volume of 2,410,185 shares, the short-interest ratio is presently 2.7 days.
In related news, Director Elaine Ullian sold 18,236 shares of Hologic stock in a transaction dated Monday, October 10th. The shares were sold at an average price of $39.88, for a total transaction of $727,251.68. Following the completion of the transaction, the director now directly owns 42,898 shares of the company’s stock, valued at approximately $1,710,772.24. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Nancy Leaming sold 8,179 shares of Hologic stock in a transaction dated Thursday, July 21st. The shares were sold at an average price of $37.00, for a total transaction of $302,623.00. Following the transaction, the director now directly owns 67,140 shares of the company’s stock, valued at $2,484,180. The disclosure for this sale can be found here. 0.84% of the stock is currently owned by insiders.
Several hedge funds have recently added to or reduced their stakes in the stock. Mizuho Asset Management Co. Ltd. raised its stake in Hologic by 89.9% in the second quarter. Mizuho Asset Management Co. Ltd. now owns 3,313 shares of the company’s stock valued at $115,000 after buying an additional 1,568 shares during the last quarter. J.Safra Asset Management Corp purchased a new stake in Hologic during the second quarter valued at approximately $115,000. Invictus RG raised its stake in Hologic by 577.0% in the second quarter. Invictus RG now owns 3,791 shares of the company’s stock valued at $131,000 after buying an additional 3,231 shares during the last quarter. Thompson Siegel & Walmsley LLC raised its stake in Hologic by 1.2% in the second quarter. Thompson Siegel & Walmsley LLC now owns 4,176 shares of the company’s stock valued at $144,000 after buying an additional 51 shares during the last quarter. Finally, Synovus Financial Corp raised its stake in Hologic by 35.6% in the second quarter. Synovus Financial Corp now owns 4,950 shares of the company’s stock valued at $171,000 after buying an additional 1,300 shares during the last quarter. 94.51% of the stock is owned by institutional investors and hedge funds.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/13/hologic-inc-holx-short-interest-update.html
HOLX has been the subject of a number of recent research reports. Bank of America Corp. reissued a “buy” rating on shares of Hologic in a research report on Wednesday, June 22nd. Leerink Swann reissued a “buy” rating and set a $46.00 price target on shares of Hologic in a research report on Thursday, July 28th. Canaccord Genuity set a $45.00 price target on shares of Hologic and gave the company a “buy” rating in a research report on Thursday, July 28th. Jefferies Group lifted their price target on shares of Hologic from $42.00 to $43.00 and gave the company a “buy” rating in a research report on Thursday, July 28th. Finally, RBC Capital Markets reissued a “sector perform” rating and set a $39.00 price target (up from $37.00) on shares of Hologic in a research report on Monday, August 1st. Six equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Hologic has a consensus rating of “Buy” and a consensus target price of $42.71.
Shares of Hologic (NASDAQ:HOLX) opened at 38.81 on Thursday. The company has a market capitalization of $10.77 billion, a price-to-earnings ratio of 42.79 and a beta of 1.00. The company’s 50-day moving average is $38.49 and its 200 day moving average is $36.32. Hologic has a 12 month low of $31.84 and a 12 month high of $41.66.
Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, July 27th. The company reported $0.51 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.48 by $0.03. The business earned $717.40 million during the quarter, compared to analyst estimates of $703.66 million. Hologic had a net margin of 9.39% and a return on equity of 26.25%. The company’s quarterly revenue was up 3.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.43 earnings per share. On average, equities research analysts anticipate that Hologic will post $1.94 earnings per share for the current year.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.